Home

Lake Titicaca Scottish Downward peg asparaginase allergic reaction pulse Rarely Harness

Overall (A), induction (B) and postinduction (C) incidence of allergic... |  Download Scientific Diagram
Overall (A), induction (B) and postinduction (C) incidence of allergic... | Download Scientific Diagram

Increase in peg-asparaginase clearance as a predictor for inactivation in  patients with acute lymphoblastic leukemia | Leukemia
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia | Leukemia

Asparaginase Toxicities: Identification and Management in Patients With  Acute Lymphoblastic Leukemia | ONS
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia | ONS

ASPARLAS (calaspargase pegol-mknl) Dosing
ASPARLAS (calaspargase pegol-mknl) Dosing

PEG - Aspraginaz - Zuvius Lifesciences
PEG - Aspraginaz - Zuvius Lifesciences

Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment  in contemporary paediatric acute lymphoblastic leukaemia protocols: a  meta-analysis of the Ponte di Legno Toxicity working group - ScienceDirect
Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group - ScienceDirect

Consensus expert recommendations for identification and management of  asparaginase hypersensitivity and silent inactivation | Haematologica
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation | Haematologica

Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic  leukemia: immunology and clinical consequences | Future Oncology
Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences | Future Oncology

Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or  Intramuscular Asparaginase Agents
Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents

Proposed treatment algorithm after allergic reactions to front-line... |  Download Scientific Diagram
Proposed treatment algorithm after allergic reactions to front-line... | Download Scientific Diagram

Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase  allergy - EJC Paediatric Oncology
Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy - EJC Paediatric Oncology

Managing Hypersensitivity to Asparaginase in Pediatrics, Adolescents, and  Young Adults | Semantic Scholar
Managing Hypersensitivity to Asparaginase in Pediatrics, Adolescents, and Young Adults | Semantic Scholar

Managing toxicities with asparaginase-based therapies in adult ALL: summary  of an ESMO Open–Cancer Horizons roundtable discussion - ScienceDirect
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion - ScienceDirect

Detecting and Treating Asparaginase-Related Toxicities in Acute  Lymphoblastic Leukemia (Transcript)
Detecting and Treating Asparaginase-Related Toxicities in Acute Lymphoblastic Leukemia (Transcript)

Managing asparaginase-related toxicity in adult patients - Oncology Nurse  Advisor
Managing asparaginase-related toxicity in adult patients - Oncology Nurse Advisor

Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia. -  Abstract - Europe PMC
Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia. - Abstract - Europe PMC

AEA measurements and 95% CI over time in the groups; Allergic reaction... |  Download Scientific Diagram
AEA measurements and 95% CI over time in the groups; Allergic reaction... | Download Scientific Diagram

A Retrospective Chart Review on the Toxicity of Pegylated Asparaginase in  Adult Patients with Acute Lymphoblastic Leukemia
A Retrospective Chart Review on the Toxicity of Pegylated Asparaginase in Adult Patients with Acute Lymphoblastic Leukemia

The severity of asparaginase-induced allergies was correlated with... |  Download Scientific Diagram
The severity of asparaginase-induced allergies was correlated with... | Download Scientific Diagram

Implementation of the asparaginase activity assessment technique for  clinical use: experience of a Brazilian Center | Scientific Reports
Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian Center | Scientific Reports

Bubble plot of the incidence of allergic reactions (sum of allergies... |  Download Scientific Diagram
Bubble plot of the incidence of allergic reactions (sum of allergies... | Download Scientific Diagram

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with  asparaginase preparations: the impact of expensive chemotherapy |  Haematologica
Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy | Haematologica

ASPARLAS (calaspargase pegol-mknl) Dosing
ASPARLAS (calaspargase pegol-mknl) Dosing

Pharmacokinetics of very prolonged PEGasparaginase and Erwinia... |  Download Scientific Diagram
Pharmacokinetics of very prolonged PEGasparaginase and Erwinia... | Download Scientific Diagram

How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia  | Future Oncology
How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia | Future Oncology

Cancers | Free Full-Text | Novel Insights on the Use of L-Asparaginase as  an Efficient and Safe Anti-Cancer Therapy
Cancers | Free Full-Text | Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy

Intravenous pegylated asparaginase versus intramuscular native Escherichia  coli l-asparaginase in newly diagnosed childhood acute lymphoblastic  leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial -  ScienceDirect
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial - ScienceDirect